These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

78 related articles for article (PubMed ID: 1775603)

  • 1. Pretreatment postural blood pressure drop as a possible predictor of response to the cholinesterase inhibitor velnacrine (HP 029) in Alzheimer's disease.
    Pomara N; Deptula D; Singh R
    Psychopharmacol Bull; 1991; 27(3):301-7. PubMed ID: 1775603
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Effectiveness and safety of velnacrine for the treatment of Alzheimer's disease. A double-blind, placebo-controlled study. Mentane Study Group.
    Antuono PG
    Arch Intern Med; 1995 Sep; 155(16):1766-72. PubMed ID: 7654110
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Do blood pressure and age predict response to tacrine (THA) in Alzheimer's disease? A preliminary report.
    Schneider LS; Lyness SA; Pawluczyk S; Gleason RP; Sloane RB
    Psychopharmacol Bull; 1991; 27(3):309-14. PubMed ID: 1775604
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Velnacrine for the treatment of Alzheimer's disease: a double-blind, placebo-controlled trial. The Mentane Study Group.
    Zemlan FP
    J Neural Transm (Vienna); 1996; 103(8-9):1105-16. PubMed ID: 9013398
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Velnacrine for Alzheimer's disease.
    Birks J; Wilcock GG
    Cochrane Database Syst Rev; 2004; (2):CD004748. PubMed ID: 15106259
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Responder characteristics to a single oral dose of cholinesterase inhibitor: a double-blind placebo-controlled study with tacrine in Alzheimer patients.
    Almkvist O; Jelic V; Amberla K; Hellström-Lindahl E; Meurling L; Nordberg A
    Dement Geriatr Cogn Disord; 2001; 12(1):22-32. PubMed ID: 11125238
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A randomized, double-blind, placebo-controlled study of the efficacy and safety of donepezil in patients with Alzheimer's disease in the nursing home setting.
    Tariot PN; Cummings JL; Katz IR; Mintzer J; Perdomo CA; Schwam EM; Whalen E
    J Am Geriatr Soc; 2001 Dec; 49(12):1590-9. PubMed ID: 11843990
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Double-blind placebo-controlled study of velnacrine in Alzheimer's disease.
    Zemlan FP; Keys M; Richter RW; Strub RL
    Life Sci; 1996; 58(21):1823-32. PubMed ID: 8637408
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A randomised double-blind placebo-controlled trial of folic acid supplementation of cholinesterase inhibitors in Alzheimer's disease.
    Connelly PJ; Prentice NP; Cousland G; Bonham J
    Int J Geriatr Psychiatry; 2008 Feb; 23(2):155-60. PubMed ID: 17600848
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Implications of the study population in the early evaluation of anticholinesterase inhibitors for Alzheimer's disease.
    Cutler NR; Sramek JJ; Murphy MF; Nash RJ
    Ann Pharmacother; 1992 Sep; 26(9):1118-22. PubMed ID: 1421679
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Caregiver time use: an outcome measure in clinical trial research on Alzheimer's disease.
    Clipp EC; Moore MJ
    Clin Pharmacol Ther; 1995 Aug; 58(2):228-36. PubMed ID: 7648773
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Efficacy and safety of donepezil in patients with more severe Alzheimer's disease: a subgroup analysis from a randomized, placebo-controlled trial.
    Feldman H; Gauthier S; Hecker J; Vellas B; Xu Y; Ieni JR; Schwam EM;
    Int J Geriatr Psychiatry; 2005 Jun; 20(6):559-69. PubMed ID: 15920715
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Atomoxetine augmentation of cholinesterase inhibitor therapy in patients with Alzheimer disease: 6-month, randomized, double-blind, placebo-controlled, parallel-trial study.
    Mohs RC; Shiovitz TM; Tariot PN; Porsteinsson AP; Baker KD; Feldman PD
    Am J Geriatr Psychiatry; 2009 Sep; 17(9):752-9. PubMed ID: 19700948
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Rivastigmine and donepezil treatment in moderate to moderately-severe Alzheimer's disease over a 2-year period.
    Bullock R; Touchon J; Bergman H; Gambina G; He Y; Rapatz G; Nagel J; Lane R
    Curr Med Res Opin; 2005 Aug; 21(8):1317-27. PubMed ID: 16083542
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Galantamine: new preparation. The fourth cholinesterase inhibitor for Alzheimer's disease.
    Prescrire Int; 2001 Dec; 10(56):180-1. PubMed ID: 11824442
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Clinical study of patients with Alzheimer's disease under treatment with tacrine].
    García-López MT; Guardado-Santervás P
    Rev Neurol; 2001 Feb 16-28; 32(4):394-7. PubMed ID: 11398762
    [No Abstract]   [Full Text] [Related]  

  • 17. The target population in phase I clinical trials of cholinergic compounds in Alzheimer disease: the role of the "bridging study".
    Cutler NR; Sramek JJ
    Alzheimer Dis Assoc Disord; 1995; 9(3):139-45. PubMed ID: 8534412
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Maximizing function in Alzheimer's disease: what role for tacrine?
    Smucker WD
    Am Fam Physician; 1996 Aug; 54(2):645-52. PubMed ID: 8701842
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Pharmacodynamic and early clinical studies with velnacrine.
    Siegfried KR
    Acta Neurol Scand Suppl; 1993; 149():26-8. PubMed ID: 8128834
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Evaluation of HP 029 (velnacrine maleate) in Alzheimer's disease.
    Murphy MF; Hardiman ST; Nash RJ; Huff FJ; Demkovich JJ; Dobson C; Knappe UE
    Ann N Y Acad Sci; 1991; 640():253-62. PubMed ID: 1776747
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 4.